Evidence map›Paper›PMID 37081019›Full record

ArticleScientific reports2023

Acute balenine supplementation in humans as a natural carnosinase-resistant alternative to carnosine.

Sarah de Jager, An Vermeulen, Siegrid De Baere, Thibaux Van der Stede, Eline Lievens, Siska Croubels, Ralf Jäger, Martin Purpura, Jan G Bourgois, Wim Derave

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 3 countries.

Sarah de JagerDepartment of Movement and Sports Sciences, Ghent University, Watersportlaan 2, 9000, Ghent, Belgium.
An VermeulenDepartment of Bioanalysis, Ghent University, Ottergemsesteenweg 460, 9000, Ghent, Belgium.
Siegrid De BaereDepartment of Pathobiology, Pharmacology and Zoological Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium.
Thibaux Van der StedeDepartment of Movement and Sports Sciences, Ghent University, Watersportlaan 2, 9000, Ghent, Belgium.
Eline LievensDepartment of Movement and Sports Sciences, Ghent University, Watersportlaan 2, 9000, Ghent, Belgium.
Siska CroubelsDepartment of Pathobiology, Pharmacology and Zoological Medicine, Ghent University, Salisburylaan 133, 9820, Merelbeke, Belgium.
Ralf JägerIncrenovo LLC, 730 E. Carlisle Avenue, Whitefish Bay, WI, 53217, USA.
Martin PurpuraIncrenovo LLC, 730 E. Carlisle Avenue, Whitefish Bay, WI, 53217, USA.
Jan G BourgoisDepartment of Movement and Sports Sciences, Ghent University, Watersportlaan 2, 9000, Ghent, Belgium.
Wim DeraveDepartment of Movement and Sports Sciences, Ghent University, Watersportlaan 2, 9000, Ghent, Belgium. wim.derave@ugent.be.
Ghent University · BEScientific Fishery Systems (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Balenine possesses some of carnosine's and anserine's functions, yet it appears more resistant to the hydrolysing CN1 enzyme. The aim of this study was to elucidate the stability of balenine in the systemic circulation and its bioavailability in humans following acute supplementation. Two experiments were conducted in which (in vitro) carnosine, anserine and balenine were added to plasma to compare degradation profiles and (in vivo) three increasing doses (1-4-10 mg/kg) of balenine were acutely administered to 6 human volunteers. Half-life of balenine (34.9 ± 14.6 min) was respectively 29.1 and 16.3 times longer than that of carnosine (1.20 ± 0.36 min, p = 0.0044) and anserine (2.14 ± 0.58 min, p = 0.0044). In vivo, 10 mg/kg of balenine elicited a peak plasma concentration (Cmax) of 28 µM, which was 4 and 18 times higher than with 4 (p = 0.0034) and 1 mg/kg (p = 0.0017), respectively. CN1 activity showed strong negative correlations with half-life (ρ = - 0.829; p = 0.0583), Cmax (r = - 0.938; p = 0.0372) and incremental area under the curve (r = - 0.825; p = 0.0433). Overall, balenine seems more resistant to CN1 hydrolysis resulting in better in vivo bioavailability, yet its degradation remains dependent on enzyme activity. Although a similar functionality as carnosine and anserine remains to be demonstrated, opportunities arise for balenine as nutraceutical or ergogenic aid.

Indexed as

CarnosineAnserineDietary SupplementsDipeptidasesDipeptidesHumansaminoacyl-histidine dipeptidaseAnserineCarnosineDipeptidasesDipeptidesN(beta)-alanyl-1-methyl-histidine

Identifiers

PMID37081019
PMCPMC10119279
OpenAlexW4366549533

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.